First 10 runs free
    Intelligence Feed event · Policy · 2026-10-26

    Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer Trial

    Question

    Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer Trial

    Direct answer

    GlobeNewswire reports that Johnson & Johnson announced positive clinical results from the Phase 1b/2 OrigAMI-4 study assessing subcutaneous amivantamab in combination with pembrolizumab and carboplatin in patients with first-line advanced head and neck squamous cell carcinoma. The triple combination achieved a 77% overall response rate in non-HPV-associated metastatic disease, reinforcing the drug's label expansion potential beyond established thoracic indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-27

    Cite as: Market Ontology, “Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer Trial”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/johnson-johnson-reports-77-response-rate-in-origami-4-head-and-neck-cancer-trial-774658

    POLICY
    Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer Trial
    GlobeNewswire reports that Johnson & Johnson announced positive clinical results from the Phase 1b/2 OrigAMI-4 study assessing subcutaneous amivantamab in combination with pembrolizumab and carboplatin in patients with first-line advanced head and neck squamous cell carcinoma. The triple combination achieved a 77% overall response rate in non-HPV-associated metastatic disease, reinforcing the drug's label expansion potential beyond established thoracic indications.
    JNJ
    Impact
    65
    OCT 26
    SIG
    90%
    JNJ
    Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer Trial
    GlobeNewswire reports that Johnson & Johnson announced positive clinical results from the Phase 1b/2 OrigAMI-4 study assessing subcutaneous amivantamab in combination with pembrolizumab and carboplatin in patients with first-line advanced head and neck squamous cell carcinoma. The triple combination achieved a 77% overall response rate in non-HPV-associated metastatic disease, reinforcing the drug's label expansion potential beyond established thoracic indications.
    → High objective response data in first-line oncology indications supports pipeline label expansion into multi-billion dollar solid tumor addressable markets.
    Impact
    GlobeNewswire reports that Johnson & Johnson announced positive clinical results from the Phase 1b/2 OrigAMI-4 study assessing subcutaneous amivantamab in combination with pembrolizumab and carboplatin in patients with first-line advanced head and neck squamous cell carcinoma. The triple combination achieved a 77% overall response rate in non-HPV-associated metastatic disease, reinforcing the drug's label expansion potential beyond established thoracic indications.
    Affected
    JNJ
    Transmission
    High objective response data in first-line oncology indications supports pipeline label expansion into multi-billion dollar solid tumor addressable markets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJoncology franchise pipeline net present value accretionUp1-4wSubcutaneous amivantamab combo demonstrated 77% ORR in first-line advanced head and neck squamous cell carcinoma.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards